Alzheimer’s Disease/Dementia News

Donanemab, an investigational antibody that targets a modified form of beta amyloid, yielded “modestly less” cognitive and functional decline than placebo among patients with early symptomatic Alzheimer’s disease in a phase 2 trial.

Intensive BP reduction in hypertension was associated with greater changes in hippocampal volume, but not any other MRI biomarkers for Alzheimer’s disease, compared with standard treatment, according to data published in JAMA Neurology.

Gait variability — or the stride-to-stride fluctuations in distance and time when moving — served as a marker of cognitive-cortical dysfunction, according to findings published in Alzheimer’s & Dementia.

About one of four patients with breast cancer experienced cognitive impairment, and it was “not exclusively related” to the patient’s therapy, researchers wrote in Psycho-Oncology.

A genome-wide analysis of patients with Lewy body dementia and healthy controls identified five independent risk loci associated with Lewy body dementia, according to findings published in Nature Genetics.

Women appear to have greater cognitive reserve but faster cognitive decline vs. men, according to results of a cohort study published in JAMA Network Open.

When examined with an FDA-approved, clinically relevant method, flortaucipir PET scans provided “valuable information” about risk for clinical decline in patients with Alzheimer’s disease and mild cognitive impairment, according to a study.

Dietary protein from different sources was associated with varying risk for CVD mortality and death from dementia or cancer among older women, according to research published in the Journal of the American Heart Association.

Increased white matter hyperintensities occurred frequently among patients with behavioral-variant frontotemporal dementia and Alzheimer’s disease in a cross-sectional MRI study published in Neurology.

CV risk factors, particularly hypertension, were linked to impaired brain metabolism tied to cognitive decline and were identifiable at midlife among asymptomatic patients with subclinical atherosclerosis, researchers reported.